April 5, 2022 7:34am
A weak Monday aftermarket, an indication and upon what are portfolios relying ?
News: bluebird bio (BLUE) announced a comprehensive restructuring intended to deliver up to $160 million in cost savings over the next two years sharpening its focus on near-term catalysts, including anticipated FDA approvals for its gene therapies for beta-thalassemia and cerebral adrenoleukodystrophy in 2022, and the potential submission of a biologics license application (BLA) for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease
Pre-open indications: 7 SELLs and 1 BUY
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.25% (-87 points), S&P futures are DOWN -0.26% (-12 points) and NASDAQ futures are DOWN -0.27% (-43 points)
Stock futures are down and slipping in pre-open trading Tuesday,
European markets were trading flat and guardedly,
Asia-Pacific markets were mixed as the Reserve Bank of Australia kept its cash rate target unchanged.
Henry’omics:
The week began with the Dow rising about 103.61 points or +0.30%, the S&P 500 advanced +36.78 points or +0.81%, while the Nasdaq rose 271.05 points or +1.90%.
The new quarter has kicked off after the major averages finished their worst quarter in two years. Investors are awaiting the Federal Reserve meeting minutes Wednesday for further clues on the central bank’s rate-hike path. Meanwhile, the first-quarter corporate earnings season is set to begin next week. <CNBC>
RegMed Investors’ (RMi) closing bell: “back on top in a tricky environment for cell and gene therapy sector equities” … https://www.regmedinvestors.com/articles/12373
Ebb and flow –
Q2/22 – 2 positive close
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (VSTM, BCLI and ADVM) 34 total to date
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …
SELL into Strength:
CRISPR Therapeutics (CRSP) +$3.36 after Friday’s +$3.38, Thursday’s -$1.31, Wednesday’s -$1.87 and last Tuesday’s +$3.12 with a negative -$0.01 or -0.01% pre-open indication
Beam Therapeutics (BEAM) +$2.41 after Friday’s +$2.65, Thursday’s -$2.15, Wednesday’s -$2.57 and last Tuesday’s +$2.97 with a positive +$0.48 or +0.77% pre-open indication,
Fate Therapeutics (FATE) +$1.07 after Friday’s +$2.55, Thursday’s -$1.09, Wednesday’s -$2.08 and last Tuesday’s +$3.94 with a positive +$1.58 or +3.73% pre-open indication,
Sage Therapeutics (SAGE) +$0.99 after Friday’s +$3.90 with a neutral $0.00 pre-open indication,
Ultragenyx (RARE) +$0.78 after Friday’s +$4.75 with a negative -$3.90 or -4.49% pre-open indication,
Maintaining SELL:
Global Blood Therapeutics (GBT) closed up +$1.39 to $37.30 after Friday’s +$1.27, Thursday’s -$0.31 and Wednesday’s -$0,54 with a positive +$0.54 or +1.45% pre-open indication
BUY the Dip:
Alnylam Pharmaceuticals (ALNY) closed down -$7.52 or -4.44% to $161.77 and has a +$3.23 or +2% pre-open indication
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed up +$0.49 with 8,809 shares traded after Friday’s flat with 16 shares traded, Thursday’s -$0.10 with 124 shares traded, Wednesday’s +$0.50 with 3,932 shares traded, and last Tuesday’s -$0.50 with 3,330 shares traded. Post earning’s release …WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion?
The BOTTOM LINE: I think and feel even if not today, the cell and gene therapy sector is in the midst of a yet another slow pullback.
It is all dependent on the stock market rally run-up through, breaking past fresh resistance levels. Then the major indexes pulled back, with the Nasdaq stopping short of the 200-day line.
Is this a signal for a return of sector rotation or just a narrow rally?
Reiterating, keep positions small and diversified amid modest overall exposure to limit any fallout. Taking profits quickly and cutting losers quickly is still vital
Reiterating, “An odd quote that caught my eye and some feelings, “To paraphrase the Rolling Stones, you can't always get what you want, but sometimes you get what you need.”
Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
